

Xizhou Zhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4141765/publications.pdf>

Version: 2024-02-01

11
papers

649
citations

1478505

6
h-index

1372567

10
g-index

12
all docs

12
docs citations

12
times ranked

1717
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity of a DNA vaccine candidate for COVID-19. Nature Communications, 2020, 11, 2601.	12.8	514
2	DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity. JCI Insight, 2019, 4, .	5.0	36
3	In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity. Advanced Science, 2020, 7, 1902802.	11.2	30
4	Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases. Frontiers in Medical Technology, 2020, 2, 571030.	2.5	29
5	Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection. Cell Reports, 2022, 38, 110318.	6.4	17
6	A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens. IScience, 2021, 24, 102699.	4.1	15
7	DNA-Encoded Glutamine Synthetase Enzyme as Ammonia-Lowering Therapeutic for Hyperammonemia. Nucleic Acid Therapeutics, 2020, 30, 379-391.	3.6	2
8	DNA immunotherapy targeting BRF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas. Molecular Therapy - Oncolytics, 2022, 24, 218-229.	4.4	2
9	Synthetic DNA Delivery of an Engineered Arginase Enzyme Can Modulate Specific Immunity In Vivo. Molecular Therapy - Methods and Clinical Development, 2020, 18, 652-663.	4.1	1
10	Nanoparticle Vaccines: In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity (Adv.) Tj ETQq0 0.2rgBT /Overlock 1		
11	Abstract 1547: DNA-encoded bispecific T-cell engagers and antibodies present long-term antitumor activity. , 2019, , .		0